

## **PYC THERAPEUTICS Q1 INVESTOR CALL**

*PYC Therapeutics will host an investor call on Friday 17 February to provide an update to shareholders on progress made through Q4 2022 and the early parts of Q1 2023*

**PERTH, Australia and SAN FRANCISCO, California – 10 February 2023**

**PYC is a drug discovery and development company creating RNA therapies for patients who have no treatment options today**

**The Company is progressing multiple first-in-class drug candidates with the potential to address the underlying cause of genetic diseases into clinical trials**

**PYC's most advanced program, a treatment for a progressive blinding eye disease is expected to progress into clinical (human) trials in the current half**

PYC Therapeutics CEO Dr. Rohan Hockings will host an investor call on **17 February, 2023 at 9am AWST** (12pm AEST, 5pm USA PST) to provide an update on recent progress made by the Company.

The investor call will be held in the McCusker Auditorium, Harry Perkins Institute, 6 Verdun Street, Nedlands, Western Australia for investors who wish to attend in person.

The audio and video link will be available 5 minutes prior to the commencement of the call.

Investors can register for the call via the zoom registration link and submit questions for the Q&A session by emailing [info@pyctx.com](mailto:info@pyctx.com).

Register in advance for this webinar:

[https://us02web.zoom.us/webinar/register/WN\\_L0bjEHIGTuiK7y056L4pUg](https://us02web.zoom.us/webinar/register/WN_L0bjEHIGTuiK7y056L4pUg)

After registering, you will receive a confirmation email containing information about joining the webinar.

### **About PYC Therapeutics**

PYC Therapeutics (ASX: PYC) is a biotechnology company creating a new generation of RNA therapies by combining its drug design capabilities with a proprietary drug delivery platform.

The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including two programs focused on inherited eye diseases and pre-clinical discovery programs focused on neurodevelopmental and kidney diseases. PYC's discovery, pre-clinical and laboratory operations are in Australia and its translational, clinical, and regulatory operations are in the United States. For more information, visit [pyctx.com](https://pyctx.com), or follow us on [LinkedIn](#) and [Twitter](#).

### **Forward looking statements**

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorized for release by the CEO of PYC Therapeutics Limited*

### **CONTACT:**

info@pyctx.com